市場調查報告書
商品編碼
1402958
腸躁症 (IBS) 治療市場 - 成長、未來前景、競爭分析,2023-2031 年Irritable Bowel Syndrome Treatment Market - Growth, Future Prospects and Competitive Analysis, 2023 - 2031 |
腸躁症(IBS)治療市場預計在2023-2031年預測期間內複合年增長率為10.5%。IBS 治療在緩解 IBS 患者的症狀方面發揮著重要作用,IBS 是一種以腹痛、腹脹和排便習慣改變為特徵的胃腸道疾病。截至 2022 年,在人們對 IBS 的認識不斷提高以及對有效治療的需求的推動下,該市場將呈現穩定成長。由於對 IBS 認識的提高、治療方案的進步以及患病率的上升,預計 IBS 市場將持續成長。治療限制仍然是一個障礙。領先公司透過技術創新和以患者為中心的策略保持競爭優勢,預計銷售額從 2022 年到 2031 年將有所成長。展望 2023 年至 2031 年,隨著新的治療方案和地理擴張,市場預計將繼續發展。
對IBS的認識不斷提高
2022年,由於一般民眾對腸躁症(IBS)的認識不斷提高,腸躁症(IBS)治療市場出現顯著成長。越來越多的人認識到這些症狀並尋求診斷和治療。這種認知的提高導致了對腸躁症治療的需求增加,而認知是關鍵驅動因素。預計這一趨勢將在 2023 年至 2031 年期間繼續成為主要驅動力。
IBS 治療的進展
IBS 治療的進步也推動了市場。正在引入新的藥物和治療方法,包括處方藥和非處方藥,以緩解腸躁症症狀。這些治療可改善個人的生活品質並提供多種選擇。治療方法的持續進步,預計將在預測期內推動市場以高複合年增長率成長。
IBS 盛行率上升
另一個重要的推動因素是IBS盛行率的上升。IBS 影響著世界上很大一部分人口,是一種常見的胃腸道疾病。由於腸躁症是一種慢性疾病,患者需要持續治療,促進了市場的成長。IBS 的盛行率持續上升,預計 2023 年至 2031 年對治療方案的需求將會增加。
腸躁症(IBS)治療市場的限制因素
儘管腸躁症(IBS)治療市場不斷成長,但仍面臨與治療限制相關的限制因素。2022 年,IBS 的治療重點是控制症狀,而不是解決根本原因。缺乏明確的治療是一個阻礙因素。這種治療限制預計將在 2023 年至 2031 年持續存在,因此需要繼續努力開發更有效的治療方法。
按類型細分市場:IBS-D 藥物主導市場
腸躁症(IBS)治療市場依類型可分為IBS-C(以便秘型為主)及IBS-D(以腹瀉型為主)。由於 IBS-D 亞型的高盛行率,到 2022 年,IBS-D 藥物的銷售額將最高。然而,在 2023 年至 2031 年的預測期內,IBS-C 療法預計將顯示出最高的複合年增長率,表明該亞型需要更有效的治療方案。
按產品細分市場:Lindseth/Constella 主導市場
另一個重要的細分因素是IBS治療產品類別,分為Xifaxan、Linzess/Constella、Viberzi、Amitiza等。2022 年,Lindseth/Constella 的銷售額最高,該藥物因其在症狀管理方面的有效性而聞名。然而,在2023年至2031年的預測期內,Xifaxane作為解決IBS症狀的有針對性的方法並在患者中越來越受歡迎,預計將表現出最高的複合年增長率。
北美仍處於世界領先地位
依地區劃分,腸躁症(IBS)治療市場呈現不同的趨勢。由於成熟的醫療保健系統和對腸躁症的高度認識,北美地區在 2022 年創下了最高的銷售比率。然而,由於新興市場對 IBS 治療的認識和獲取不斷增加,亞太地區預計 2023 年至 2031 年複合年增長率最高。
預測期內市場競爭將加劇
腸躁症(IBS)治療市場包括Allergan、Takeda、AbbVie.、Takeda、Pfizer, Inc.、Abbott Laboratories、Novartis AG、AstraZeneca PLC、Ironwood Pharmaceuticals Inc.、Bausch Health Companies Inc.、GlaxoSmithKline , Plc.、Lexicon Pharmaceuticals, Inc.、Sucampo Pharmaceuticals, Inc.等。這些公司持續投資於研發,以改善 IBS 治療並擴大其市場份額。2022年已錄得可觀利潤,由於策略投資,預計2023年至2031年將獲得高額利潤。關鍵策略包括引入新的治療方案、改善患者支援以及擴大我們的分銷網絡以覆蓋更多需要 IBS 治療的人。
本報告回答的關鍵問題
影響腸躁症(IBS)治療市場成長的關鍵微觀和宏觀環境因素有哪些?
現在和預測期內,就產品領域和地區而言,主要投資領域為何?
2031 年之前的預估與市場預測
在預測期間內,哪個細分市場的複合年增長率最快?
哪個細分市場擁有較大的市場份額,為什麼?
低收入和中等收入國家是否正在投資腸躁症(IBS)治療市場?
腸躁症(IBS)治療市場最大的區域市場是哪一個?
亞太、拉丁美洲、中東/非洲等新興市場的市場趨勢與動態如何?
推動腸躁症(IBS)治療市場成長的主要趨勢是什麼?
主要競爭對手有哪些,以及他們提高在全球腸躁症 (IBS) 治療市場中的影響力的關鍵策略是什麼?
The irritable bowel syndrome (IBS) treatment market is expected to grow at a CAGR of 10.5% during the forecast period of 2023 to 2031. IBS treatment plays a vital role in providing relief to individuals suffering from IBS, a gastrointestinal disorder characterized by abdominal pain, bloating, and changes in bowel habits. As of 2022, the market exhibited steady growth, driven by increased awareness of IBS and the demand for effective treatments. The IBS market is poised for continued growth, driven by growing awareness of IBS, advancements in treatment options, and the rising prevalence of the condition. Treatment limitations remain a restraint. Key players are expected to maintain their competitive edge through innovation and patient-focused strategies, with revenues projected to rise from 2022 to 2031. Looking ahead to the period from 2023 to 2031, the market is expected to continue evolving with new treatment options and geographic expansion.
Growing Awareness of IBS
In 2022, the Irritable Bowel Syndrome Treatment Market witnessed significant growth due to the increasing awareness of IBS among the general population. More individuals are recognizing the symptoms and seeking diagnosis and treatment. This growing awareness led to higher demand for IBS treatments, making awareness a crucial driver. This trend is expected to continue as a key driver from 2023 to 2031.
Advancements in IBS Treatment
The market was also driven by advancements in IBS treatment options. New medications and therapies, both prescription and over-the-counter, have been introduced to provide relief from IBS symptoms. These treatments offer a range of options for individuals, improving their quality of life. As advancements in treatment continue, they are expected to drive market growth with a high CAGR during the forecast period.
Rising Prevalence of IBS
Another significant driver was the rising prevalence of IBS. The condition affects a substantial portion of the global population, making it a common gastrointestinal disorder. With IBS being a chronic condition, individuals require ongoing treatment, contributing to the market's growth. As the prevalence of IBS continues to rise, it is expected to drive demand for treatment options from 2023 to 2031.
Restraint in the Irritable Bowel Syndrome Treatment Market
Despite its growth, the Irritable Bowel Syndrome Treatment Market faces a restraint related to treatment limitations. In 2022, treatments for IBS focused on symptom management, rather than addressing the root cause of the condition. The absence of a definitive cure acted as a restraint. It is expected that this treatment limitation will continue to be a challenge from 2023 to 2031, necessitating ongoing research efforts to develop more effective treatments.
Market Segmentation by Type: IBS-D treatments Dominate the Market
The Irritable Bowel Syndrome Treatment Market can be segmented by type into IBS-C (Constipation-predominant) and IBS-D (Diarrhea-predominant). In 2022, the highest revenue was attributed to IBS-D treatments, given the high prevalence of this IBS subtype. However, during the forecast period from 2023 to 2031, IBS-C treatments are expected to exhibit the highest CAGR, indicating the need for more effective treatment options for this subtype.
Market Segmentation by Product: Linzess/Constella Dominate the Market
Another crucial segmentation factor is the product category of IBS treatments, which can be divided into Xifaxan, Linzess/Constella, Viberzi, Amitiza, and others. In 2022, the highest revenue came from Linzess/Constella, which are known for their effectiveness in symptom management. However, during the forecast period from 2023 to 2031, Xifaxan is expected to exhibit the highest CAGR, as it offers a targeted approach in addressing IBS symptoms and gaining popularity among patients.
North America Remains the Global Leader
Geographically, the Irritable Bowel Syndrome Treatment Market exhibits diverse trends. North America recorded the highest revenue percentage in 2022, driven by a well-established healthcare system and high awareness of IBS. However, the Asia-Pacific region is expected to have the highest CAGR from 2023 to 2031, as awareness and access to IBS treatments grow in emerging markets.
Market Competition to Intensify during the Forecast Period
The Irritable Bowel Syndrome Treatment Market is characterized by competition among key players, such as Allergan, Takeda Pharmaceutical Company, AbbVie., Takeda Pharmaceutical Company Limited, Pfizer, Inc., Abbott Laboratories, Novartis AG, AstraZeneca PLC, Ironwood Pharmaceuticals Inc., Bausch Health Companies Inc., GlaxoSmithKline, Plc., Lexicon Pharmaceuticals, Inc. and Sucampo Pharmaceuticals, Inc. These companies have consistently invested in research and development to improve IBS treatments and expand their market presence. In 2022, they recorded substantial revenues, and it is expected that their strategic investments will continue to yield high returns from 2023 to 2031. Key strategies include introducing new treatment options, improving patient support, and expanding distribution networks to reach more individuals in need of IBS treatment.
Historical & Forecast Period
This study report represents analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation ofIrritable Bowel Syndrome Treatment market are as follows:
Research and development budgets of manufacturers and government spending
Revenues of key companies in the market segment
Number of end users and consumption volume, price and value.
Geographical revenues generate by countries considered in the report:
Micro and macro environment factors that are currently influencing the Irritable Bowel Syndrome Treatment market and their expected impact during the forecast period.
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
Market Segmentation
Type
Product
Region Segment (2021-2031; US$ Million)
North America
U.S.
Canada
Rest of North America
UK and European Union
UK
Germany
Spain
Italy
France
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East and Africa
GCC
Africa
Rest of Middle East and Africa
Key questions answered in this report:
What are the key micro and macro environmental factors that are impacting the growth of Irritable Bowel Syndrome Treatment market?
What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
Estimated forecast and market projections up to 2031.
Which segment accounts for the fastest CAGR during the forecast period?
Which market segment holds a larger market share and why?
Are low and middle-income economies investing in the Irritable Bowel Syndrome Treatment market?
Which is the largest regional market for Irritable Bowel Syndrome Treatment market?
What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
Which are the key trends driving Irritable Bowel Syndrome Treatment market growth?
Who are the key competitors and what are their key strategies to enhance their market presence in the Irritable Bowel Syndrome Treatment market worldwide?
TABLE 3 Global Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 4 Global Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 7 North America Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 8 North America Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 11 U.S. Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 12 U.S. Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 15 Canada Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 16 Canada Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 19 Rest of North America Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 20 Rest of North America Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 23 UK and European Union Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 24 UK and European Union Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 27 UK Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 28 UK Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 31 Germany Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 32 Germany Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 35 Spain Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 36 Spain Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 39 Italy Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 40 Italy Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 43 France Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 44 France Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 47 Rest of Europe Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 48 Rest of Europe Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 51 Asia Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 52 Asia Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 55 China Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 56 China Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 59 Japan Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 60 Japan Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 63 India Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 64 India Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 67 Australia Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 68 Australia Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 71 South Korea Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 72 South Korea Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 75 Latin America Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 76 Latin America Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 79 Brazil Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 80 Brazil Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 83 Mexico Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 84 Mexico Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 87 Rest of Latin America Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 88 Rest of Latin America Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 91 Middle East and Africa Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 92 Middle East and Africa Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 95 GCC Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 96 GCC Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 99 Africa Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 100 Africa Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
TABLE 103 Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Market By IBS-D, 2021-2031, USD (Million)
TABLE 104 Rest of Middle East and Africa Irritable Bowel Syndrome Treatment Market By Product, 2021-2031, USD (Million)
FIG. 9Market Positioning of Key Irritable Bowel Syndrome Treatment Market Players, 2022
FIG. 10Global Irritable Bowel Syndrome Treatment Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031